scholarly journals Oral anticoagulation in chronic kidney disease with atrial fibrillation

2021 ◽  
Author(s):  
Pablo Gomez -Fernández ◽  
Antonio Martín Santana ◽  
Juan de Dios Arjona Barrionuevo
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Oral Anticoagulation

Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist’s perspective

2020 ◽  
Vol 33 (3) ◽  
pp. 483-495 ◽  
Author(s):  
Maura Ravera ◽  
Elisabetta Bussalino ◽  
Maria Fusaro ◽  
Luca Di Lullo ◽  
Filippo Aucella ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Oral Anticoagulation

The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease

2016 ◽  
Vol 117 (3) ◽  
pp. 477-482 ◽  
Author(s):  
Shmuel Schwartzenberg ◽  
Eli I. Lev ◽  
Alexander Sagie ◽  
Asher Korzets ◽  
Ran Kornowski
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Oral Anticoagulation

Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study

EP Europace ◽  
2019 ◽  
Vol 22 (5) ◽  
pp. 716-723
Author(s):  
Mathias Aagaard Christensen ◽  
Emil Loldrup Fosbøl ◽  
Anders Nissen Bonde ◽  
Jonas Bjerring Olesen ◽  
Gunnar H Gislason ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Ischaemic Stroke ◽  
Antiplatelet Therapy ◽  
Oral Anticoagulation ◽  
Multivariable Analysis ◽  
Thromboembolic Events ◽  
Post Stroke ◽  
Significant Difference

Abstract Aims Oral anticoagulation (OAC) therapy as secondary stroke prophylaxis in atrial fibrillation (AF) patients with chronic kidney disease (CKD) remains unexplored and poses a clinical treatment dilemma. We assessed the long-term risk of thromboembolic events according to post-stroke OAC therapy in AF patients with CKD after their first ischaemic stroke. Methods and results We identified Danish AF patients with CKD who presented with first-time ischaemic stroke from 2005 to 2014. Chronic kidney disease was defined as a diagnosis code for CKD before baseline, defined as 100 days after stroke discharge. Post-stroke antithrombotic therapy (OAC therapy and antiplatelet therapy) was identified from prescription claims from discharge to baseline. Cumulative incidences and adjusted hazard ratios (HRs) of thromboembolic events according to post-stroke OAC therapy were examined. Of 1252 AF patients with CKD presenting with ischaemic stroke, 631 (50.4%) patients were on OAC therapy and 621 (49.6%) were on antiplatelet therapy alone at baseline [median age 76 (interquartile range, IQR 71–83) and 80 (IQR 72–86), respectively]. The median follow-up period was 1.9 years (IQR 0.8–3.6). Cumulative incidence rates of thromboembolic events and bleeding showed no significant difference between those on OAC therapy and antiplatelet therapy. The results from the multivariable analysis revealed similar results: thromboembolic risk was not modified by OAC treatment [adjusted HR 0.89, 95% confidence interval (CI) 0.73–1.09] nor was the risk of bleeding (adjusted HR 0.88, 95% CI 0.67–1.17). Conclusion Oral anticoagulation in patients with CKD and prior stroke was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy.

Oral anticoagulation in patients with atrial fibrillation and chronic kidney disease

2015 ◽  
Vol 144 (10) ◽  
pp. 480
Author(s):  
Luis Angel Sánchez-Muñoz ◽  
René Arnaldo Aguilar-Flores ◽  
Ana Juanatey-García ◽  
Sara González de Zárate-Catón
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Oral Anticoagulation

scholarly journals P3845Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease: a nationwide cohort study

2018 ◽  
Vol 39 (suppl_1) ◽  
Author(s):  
A Nissen Bonde ◽  
G Y H Lip ◽  
A L Kamper ◽  
G Gislason ◽  
C Torp-Pedersen ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Kidney Disease ◽  
Oral Anticoagulation

ORAL ANTICOAGULATION UNDERUSED AND ASPIRIN OVERUSED FOR ATRIAL FIBRILLATION WITH ADVANCED CHRONIC KIDNEY DISEASE STATUS

2019 ◽  
Vol 73 (9) ◽  
pp. 408 ◽  
Author(s):  
Michael Dorsch ◽  
Sean Pokorney ◽  
Mary Birmingham ◽  
John A. House ◽  
Kenneth Moore ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Oral Anticoagulation ◽  
Disease Status ◽  
Advanced Chronic Kidney Disease

Oral anticoagulation in chronic kidney disease with atrial fibrillation

2015 ◽  
Vol 144 (10) ◽  
pp. 452-456
Author(s):  
Víctor Expósito ◽  
Miguel Seras ◽  
Gema Fernández-Fresnedo
Keyword(s):  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Oral Anticoagulation

Pathophysiology of atrial fibrillation and chronic kidney disease

2020 ◽  
Author(s):  
Wern Yew Ding ◽  
Dhiraj Gupta ◽  
Christopher F Wong ◽  
Gregory Y H Lip
Keyword(s):  
Risk Factors ◽  
Atrial Fibrillation ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Oral Anticoagulation ◽  
Stroke Prevention ◽  
Bleeding Complications ◽  
Stroke Management ◽  
Underlying Mechanisms ◽  
Shared Risk

Abstract Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely related conditions with shared risk factors. The growing prevalence of both AF and CKD indicates that more patients will suffer from concurrent conditions. There are various complex interlinking mechanisms with important implications for the management of these patients. Furthermore, there is uncertainty regarding the use of oral anticoagulation (OAC) in AF and CKD that is reflected by a lack of consensus between international guidelines. Therefore, the importance of understanding the implications of co-existing AF and CKD should not be underestimated. In this review, we discuss the pathophysiology and association between AF and CKD, including the underlying mechanisms, risk of thrombo-embolic and bleeding complications, influence on stroke management, and evidence surrounding the use of OAC for stroke prevention.

Sign in / Sign up

Export Citation Format

Share Document